![BONIVA (ibandronate [as monosodium monohydrate]) 150mg tablets by Roche](http://media.empr.com/images/2013/01/16/boniva-150mg_335269_335270.jpg "BONIVA (ibandronate [as monosodium monohydrate]) 150mg tablets by Roche")
Generic Name and Formulations:
Ibandronate (as monosodium monohydrate) 150mg; tabs.
Company:
Roche Laboratories
Prevention and treatment of postmenopausal osteoporosis.
Swallow whole. Take in the AM with plain (not mineral) water (6–8oz), at least 60 minutes before the first food, drink, or medication of the day; do not lie down for at least 60 minutes after. 150mg once monthly (take on the same day each month). Do not take two 150mg tablets within the same week.
Not recommended.
Bisphosphonate.
Hypocalcemia. Tabs: Esophagus abnormalities which delay esophageal emptying (eg, stricture, achalasia). Inability to stand or sit upright for at least 60 minutes.
Active upper GI disease; discontinue and reevaluate if signs/symptoms of esophageal reaction occur. Severe renal impairment (CrCl <30mL/min): not recommended. Correct preexisting hypocalcemia, other mineral or bone disturbances before starting. History of bisphosphonate exposure: evaluate for atypical fractures if thigh/groin pain develops; consider withholding therapy until risk/benefit assessment. Ensure adequate Vit. D and calcium intake. Reevaluate periodically. Inj: check renal function before each dose. Pregnancy (Cat.C). Nursing mothers.
Calcium, aluminum, magnesium, other divalent cations reduce absorption (separate dosing). Caution with aspirin, NSAIDs, other GI irritants. May interfere with bone-imaging agents. Concomitant nephrotoxic agents; monitor for renal toxicity.
GI upset, abdominal pain, musculoskeletal pain (may be severe), headache; dysphagia, esophagitis, esophageal or gastric ulcer, jaw osteonecrosis; atypical femur fractures. Inj: inj site reactions, flu-like syndrome.
Tabs 150mg—3; Prefilled syringe (5mL)—1 (w. supplies)